2020 AABB Annual Meeting On-Demand: Cellular Therapy Sessions


Interested in all things Cellular Therapies? Then this is the package for you. We have also thrown in a couple of additional sessions you might also find interesting.

The package includes 17 sessions (1 in Spanish) which provide you the opportunity to earn up to 16 general credits; 15 continuing medical education credits for physicians; or, 16 California Lab Personnel, Florida Lab Personnel or California Nurse contact hours.

Purchase of this package includes the on-demand recording and a downloadable MP3 audio file for each session. Presentation handouts are not available/included.

If purchasing these sessions separately it would cost $320/$400 (member/nonmember).

Access is available through December 31, 2022 so purchase this package today.

Members: $199.00
Standard: $249.00

Products

AM20-03: iPSCs for the Treatment of Beta Hemoglobinopathies

Preview Available

AM20-03: iPSCs for the Treatment of Beta Hemoglobinopathies

Oct 3, 2020 10:00am ‐ Oct 3, 2020 11:00am

Presented in collaboration with Be The Match BioTherapies®

Induced pluripotent stem cells (iPSCs), derived from adult cells, have the potential to form any cell type in the body. iPSCs are promising research tools for studying human development, modeling disease and potentially treating patients. Hemoglobinopathies such as sickle cell disease (SCD) and beta thalassemia (BT) are treated with a limited number of pharmacologic options and blood transfusions. The only curative treatment modality is allogeneic transplantation and autologous transplantation with hematopoietic progenitor cell (HPC)-based gene therapy but these approaches have limitations and the latter is still in clinical trials. HPC-based approaches require obtaining sufficient numbers of HPCs via a bone marrow harvest or peripheral blood stem cell collection and maintaining the HPCs ex vivo for more than a short period of time for ex vivo manipulation without a loss of engraftment ability which are challenging to do. iPSCs may offer potential benefits over HPC-based approaches. This session will provide information on the current state of iPSCs for the treatment of hemoglobinopathies.

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-04: Essential Twitter for Blood Banking and Cellular Therapy Professionals

Preview Available

AM20-04: Essential Twitter for Blood Banking and Cellular Therapy Professionals

Oct 3, 2020 11:15am ‐ Oct 3, 2020 12:15pm

Using specific examples, we will begin by discussing personal versus professional use of social media. Next, we will discuss different examples of how educational content (#blooducation) is presented on social media including Twitter Chats and articles, paving the way for inclusive conversations on blood banking and cellular therapy topics. Then, in small groups, we will apply these skills in a friendly competition for the title of “Best Tweetorial” as judged by some of AABB’s social media celebrities.

At the end of the session, we hope that you will take away new technical skills and an increased level of confidence to participate in our upcoming AABB Twitter Chats (#AABBPEPTalk) or journal clubs (#AABBjc), as well as share your own professional experiences, insights and knowledge on Twitter from the bench or beyond.

Speaker(s):
  • Dr. Daniela Hermelin, MD, Assistant Professor of Pathology, Director of Therapeutic Apheresis and Associate Director of Transfusion Medicine, St. Louis University School of Medicine
  • Dr. Justin D. Kreuter, M.D., Consultant and Instructor, Laboratory Medicine and Pathology, Mayo Clinic
  • Aaron Shmookler, MD, Medical Director of Transfusion Services, WVU Medicine
Standard: $25.00
Members: $20.00

AM20-06: Cellular Therapies for SARS-CoV2

Preview Available

AM20-06: Cellular Therapies for SARS-CoV2

Oct 3, 2020 11:15am ‐ Oct 3, 2020 12:15pm

Join us as we review the latest cellular therapy advancements for treatment in the COVID-19 pandemic. In addition to addressing the use of specific T cells in COVID-19 treatment, faculty will also discuss the importance of missing imputation for single cell sequencing (MISC) in COVID-19 analysis.

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-12: Mechanisms and Technologies Towards Expanding Hematopoietic Stem Cells for Transplantation

Preview Available

AM20-12: Mechanisms and Technologies Towards Expanding Hematopoietic Stem Cells for Transplantation

Oct 3, 2020 3:45pm ‐ Oct 3, 2020 4:45pm

Presented in collaboration with Be The Match BioTherapies®

Hematopoietic stem cells (HSCs) are the apex hematopoietic cell with the potential to produce robust and lifelong production of all blood cells. Thus, understanding the details of HSC molecular biology is critical to our understanding of human health and longevity. Mechanistic insights into HSC biology could be leveraged to further improve the strategies available to maintain and expand functional HSCs in vitro. Overcoming these hurdles is critical to effectively use HSCs for off-the-shelf allogeneic HSC transplantation or gene-editing of autologous HSCs for treatments of hematological disease and malignancies. In this session, we will examine the latest molecular mechanisms discovered thus far to harness the capacity of HSCs to maintain blood cell lineage output and durable HSC self-renewal towards development of novel methods to produce unlimited HSCs in vitro for use in transfusion applications.

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-15: Controversies in Stem Cell Tourism: Practical and Ethical Considerations

Preview Available

AM20-15: Controversies in Stem Cell Tourism: Practical and Ethical Considerations

Oct 3, 2020 6:00pm ‐ Oct 3, 2020 7:00pm

Based on a thorough review of social media, newspaper articles and scientific publications, a role for internet in influencing stem cell tourism has emerged. A tally of data from these sources suggests an increase in the number of patients exploring stem cell tourism under the pretext of “Management of Hope”. Potential participants should, however, be informed of the risk factors involved with the usage of unregulated and unproven stem cell therapies. This session will also caution clinicians and researchers in other countries to exercise restraint in using or recommending any unregulated stem cell products.

This session has three main objectives: first to educate attendees on the background, history and current trends in Stem Cell Tourism - the unregulated commercial stem-cell industry, a practice that is not only potentially harmful to individual patients but also undermines attempts to study stem-cell therapies in clinical trials. The Program Chair, Dr. Indira Guleria, will give this introductory lecture. She will discuss the perils of stem cell tourism by discussing her collaborative study (NEJM 2016) where glioproliferative lesions developed in a patient who received stem cell infusions.

Second, attendees will learn about clinical research in neurodegenerative diseases. Diseases such as traumatic brain injury, macular degeneration, cerebral palsy are common targets of stem cell tourism. These diseases have also been linked to serious complications arising because of stem cell tourism. Invited to talk about these diseases is Dr. Sally Temple, Director of the Neural Stem Cell Institute who is an expert on use of cellular therapy in neurodegenerative disease conditions.

Finally, attendees of this session will be introduced to the regulatory, legislative and ethical aspects of Stem cell Tourism. Regulation of stem cell therapy and enforcement of pre-existing legislation varies from country to country and has allowed stem cell tourism to outpace legislation in various countries. We plan to invite Dr. Henry Greely who is a Professor of Law at Stanford University and specializes in ethical, legal, and social issues arising from advances in the biosciences, particularly in human stem cell research to address the regulatory aspect of stem cell tourism.

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-18: Mechanisms of Hematopoietic Stem Cells Towards Rejuvenation of the Aging Hematopoietic System

Preview Available

AM20-18: Mechanisms of Hematopoietic Stem Cells Towards Rejuvenation of the Aging Hematopoietic System

Oct 3, 2020 7:15pm ‐ Oct 3, 2020 8:15pm

Presented in collaboration with Be The Match BioTherapies®

A hallmark of the ageing hematopoietic system is a skewing of lineage output from balanced to myeloid-biased, which is hypothesized to result in compromised adaptive immunity and predisposition toward myeloid malignancies in aging individuals. More recently, changes in the composition of a heterogeneous HSC population with age (the population shift model) is being increasingly recognized to account for lineage output changes and the observed hematopoietic ageing phenotype may result from an expansion of myeloid-biased HSCs with exhaustion of lymphoid-biased and balanced HSCs. Importantly, research efforts continue investigate the molecular mechanisms associated with aging HSCs. This session will highlight theories recent discoveries of the ageing HSC compartment and molecular mechanisms underlying these processes which potentially can be targeted to rejuvenate aged HSC functions.

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-24: Innovative Alternatives to Platelet Transfusion

Preview Available

AM20-24: Innovative Alternatives to Platelet Transfusion

Oct 4, 2020 11:15am ‐ Oct 4, 2020 12:15pm

Presented in collaboration with Be The Match BioTherapies®

The increased understanding of the biological events underlying the generation of platelets from megakaryocytes led to the development of novel strategies that might eventually supplement or replace donor-derived platelet transfusions. Ex vivo manufacturing of platelets from primary hematopoietic stem cells or from induced pluripotent stem cells has been pursued and near-clinical doses of platelets have been achieved by utilizing highly optimized ex vivo cultures and/or state-of-the-art bioreactors. In addition, megakaryocyte-biased cellular products that have the ability to naturally release platelets in the patient’s own body after infusion have been proposed to mitigate repeated platelet transfusions. Clinical implementation of these approaches has the potential to overcome the limitations associated with donor-dependent platelet transfusions such as risk of bacterial contamination, alloimmunization and refractoriness. Furthermore, these novel strategies have the potential to mitigate the increasing demand for donor platelet transfusions which is compounded by dependency on volunteer donors, short storage time and lifespan after infusion as well as shortages in supply due to inclement weather and holidays. This session will review three different approaches to the standard platelet transfusions. Each presenter will highlight the biological basis, process and description of product development as well as manufacturing and regulatory strategies to advance these cellular products to the clinic. Attendees will require a general understanding of human thrombocytopoiesis, i.e. platelet production in vivo and ex vivo, and development of cellular products as therapeutics along with the knowledge of the clinical indications for platelet transfusions and associated risks.

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-30: Supporting Genetic Therapies for Sickle Cell Disease (ASH/AABB Joint Session)

Preview Available

AM20-30: Supporting Genetic Therapies for Sickle Cell Disease (ASH/AABB Joint Session)

Oct 4, 2020 3:45pm ‐ Oct 4, 2020 4:45pm

Presented in collaboration with Be The Match BioTherapies®

Cellular therapies for treating SCD are expanding at a rapid pace, with multiple approaches in trials and under development. Most of the therapeutic approaches use stem cell transplantation with genetically modified HSC, to generate red cells resistant to sickling. Emerging therapies include gene addition of beta globin, Bcl11a modification as well as other gene and base editing techniques being performed at both academic and industry research laboratories. While there are promising early results from clinical trials using gene therapy, more work is required to understand how to optimize stem cell collection, transplantation and engraftment.

To develop novel cell therapies, a concerted effort to link clinicians, patients, researchers and industry to move the field forward. In our session, we will review the current landscape of SCD therapies and to discuss how the initiative functions to identify and support initiatives. We will discuss the therapeutic clinical trials and review the clinical indicators used to assess successful outcomes. Lastly, we will discuss preparative transfusion therapies to optimize mobilization and collection of stem cells and to improve outcome of stem cell transplantation. The latter therapies heavily rely on the expertise of transfusion medicine specialists. Together, this presentation seeks to demonstrate the multimodal approaches of cell therapy for sickle cell disease.

The target audience is wide and includes: 

• Blood bank technicians and managers to understand transfusion needs
• Apheresis clinicians who perform red cell exchange and stem cell collection
• Hematologists and Stem Cell Transplant clinicians interested in trials and clinical therapeutic endpoints
• Patients and their advocates to understand the multi-modal nature of the novel cell therapies
• Scientific program managers that allocate resources and balance efforts within an initiative

Speaker(s):
Standard: $25.00
Members: $20.00

AM20-38: The Thin Line Between Advancement or Exploitation…the Role of the “Super Donor” in Allogeneic Cell Therapy

Preview Available

AM20-38: The Thin Line Between Advancement or Exploitation…the Role of the “Super Donor” in Allogeneic Cell Therapy

Oct 5, 2020 11:15am ‐ Oct 5, 2020 12:15pm

Discover why reliance on a small subset of “super donors” could introduce risk and ignite ethical considerations for cell and gene therapy companies seeking sustainable growth and scalability.

Speaker(s):
Standard: $25.00
Members: $20.00

Solve It! Scenarios in Cellular Therapy

Preview Available

Solve It! Scenarios in Cellular Therapy

Oct 5, 2020 12:45pm ‐ Oct 5, 2020 2:00pm

We all face challenges in our daily work activities within Cellular Therapy: What is the best approach to manage storage space? How to deal with supply and reagents shortages? How to handle the growing number of clinical trials? How to be better prepared for the next disaster? Or how to adjust training and competency programs to accommodate the changing workforce?

The Solve It! Scenarios in Cellular Therapy session offers an interactive and constructive program for Cellular Therapy Professionals to share challenges through case scenario presentations. This program permits attendees to choose from a menu of interesting topics, then rotate through multiple scenario case presentations in small, informal groups, to develop problem solving strategies. Join us for lively interactions and networking with experts in the field of Cellular Therapy and fellow colleagues. The round tables is led by the sub-sections leaders of the Cellular Therapies Section Coordinating Committee (CTSCC).

Speaker(s):
Standard: $25.00
Members: $20.00
Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content